Because the exclusive expression of the FSHR has already been described by our group as a negative prognosticator in ovarian cancer cases, our finding about enhanced expression of both FSHR and THRα in the nucleus might lead to new treatment strategies for this type of cancer (Lenhard et al. 2011). This evidence concerns the gene THRA and ovarian carcinoma.